Satomi Matsuo1,2, Junichiro Watanabe3, Koichi Mitsuya4, Nakamasa Hayashi4, Yoko Nakasu4, Mitsuhiro Hayashi2. 1. Division of Breast Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shizuoka, Japan. 2. Division of Breast Surgery, Tokyo Medical College, Hachioji Medical Center, Tokyo, Japan. 3. Division of Breast Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shizuoka, Japan. j.watanabe@scchr.jp. 4. Division of Neurosurgery, Shizuoka Cancer Center, Shizuoka, Japan.
Abstract
PURPOSE: The data of 589 metastatic breast cancer (MBC) patients in a single institution were reviewed to determine the outcomes of patients with brain metastasis (BM) and assess the efficacy of BM screening. METHODS: The patients with BM among the 589 MBC patients who underwent treatment at Shizuoka Cancer Center (Shizuoka, Japan) from 09/2002 to 03/2014 were retrospectively analyzed. RESULTS: During the study period, BM developed in 187 (31.7%) patients. The tumor subtypes were as follows: luminal (hormone receptor [HR]+, HER2-), 44.9%; luminal-HER2 (HR+, HER2+), 14.9%; HER2 (HR-, HER2+), 21.3%; and triple-negative (TN), 16.0%. BM was detected in 48.6% of the patients by screening MRI. While 137 of 187 patients underwent local therapy, whole-brain irradiation was the most frequently applied therapy (63.5%). The median overall survival from the diagnosis of BM was as follows: luminal, 7.0 months (M); luminal-HER2, 13.3 M; HER2, 17.7 M; TN, 4.2 M. The HER2 status (hazard ratio [HR]: 0.58, 95% confidence interval [CI] 0.38-0.88) and nonprogressive extracranial lesion(s) (HR: 0.45, 95% CI 0.29-0.71) were identified as prognostic factors in a multivariate analysis. When limited to HER2-overexpressed MBC patients, the multivariate analysis revealed that non-progressive extracranial lesion(s) (HR: 0.20, 95% CI 0.088-0.47) and stereotactic irradiation (STI) as an initial treatment (HR: 0.18, 95% CI 0.061-0.56) were prognostic factors. CONCLUSIONS: Our retrospective review showed that early detection of BM by screening MRI, followed by STI, improved the prognosis of HER2-overexpressed MBC patients with BM. A further prospective randomized study is needed to confirm our findings.
PURPOSE: The data of 589 metastatic breast cancer (MBC) patients in a single institution were reviewed to determine the outcomes of patients with brain metastasis (BM) and assess the efficacy of BM screening. METHODS: The patients with BM among the 589 MBCpatients who underwent treatment at Shizuoka Cancer Center (Shizuoka, Japan) from 09/2002 to 03/2014 were retrospectively analyzed. RESULTS: During the study period, BM developed in 187 (31.7%) patients. The tumor subtypes were as follows: luminal (hormone receptor [HR]+, HER2-), 44.9%; luminal-HER2 (HR+, HER2+), 14.9%; HER2 (HR-, HER2+), 21.3%; and triple-negative (TN), 16.0%. BM was detected in 48.6% of the patients by screening MRI. While 137 of 187 patients underwent local therapy, whole-brain irradiation was the most frequently applied therapy (63.5%). The median overall survival from the diagnosis of BM was as follows: luminal, 7.0 months (M); luminal-HER2, 13.3 M; HER2, 17.7 M; TN, 4.2 M. The HER2 status (hazard ratio [HR]: 0.58, 95% confidence interval [CI] 0.38-0.88) and nonprogressive extracranial lesion(s) (HR: 0.45, 95% CI 0.29-0.71) were identified as prognostic factors in a multivariate analysis. When limited to HER2-overexpressed MBCpatients, the multivariate analysis revealed that non-progressive extracranial lesion(s) (HR: 0.20, 95% CI 0.088-0.47) and stereotactic irradiation (STI) as an initial treatment (HR: 0.18, 95% CI 0.061-0.56) were prognostic factors. CONCLUSIONS: Our retrospective review showed that early detection of BM by screening MRI, followed by STI, improved the prognosis of HER2-overexpressed MBCpatients with BM. A further prospective randomized study is needed to confirm our findings.
Entities:
Keywords:
Brain metastasis; Breast cancer; HER2; Prospective screening
Authors: Daisuke Yamashita; Mutsuko Minata; Ahmed N Ibrahim; Shinobu Yamaguchi; Vito Coviello; Joshua D Bernstock; Shuko Harada; Richard A Cerione; Bakhos A Tannous; Concettina La Motta; Ichiro Nakano Journal: Mol Cancer Ther Date: 2020-03-03 Impact factor: 6.261
Authors: Amélie Darlix; Gaia Griguolo; Simon Thezenas; Eva Kantelhardt; Christoph Thomssen; Maria Vittoria Dieci; Federica Miglietta; PierFranco Conte; Antoine Laurent Braccini; Jean Marc Ferrero; Caroline Bailleux; William Jacot; Valentina Guarneri Journal: J Neurooncol Date: 2018-02-27 Impact factor: 4.130
Authors: Anurag Saraf; Christopher S Grubb; Mark E Hwang; Cheng-Hung Tai; Cheng-Chia Wu; Ashish Jani; Matthew E Lapa; Jacquelyn I S Andrews; Sierra Vanderkelen; Steven R Isaacson; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Eileen P Connolly; Tony J C Wang Journal: J Neurooncol Date: 2017-07-03 Impact factor: 4.130
Authors: Matthew N Mills; Chetna Thawani; Nicholas B Figura; Daniel E Oliver; Aixa E Soyano; Arnold Etame; Timothy J Robinson; James K Liu; Michael A Vogelbaum; Peter A Forsyth; Brian J Czerniecki; Hatem H Soliman; Hyo S Han; Hsiang-Hsuan Michael Yu; Kamran A Ahmed Journal: J Neurooncol Date: 2021-03-19 Impact factor: 4.130
Authors: Tamás Mezei; Melinda Hajdu; Gábor Czigléczki; Gábor Lotz; Judit Kocsis; Janina Kulka; Anna Horváth Journal: BMC Cancer Date: 2020-07-01 Impact factor: 4.430